One-year data showed sustained benefit for once-weekly canvuparatide as a potential parathyroid hormone (PTH) replacement therapy in chronic hypoparathyroidism. The Phase 3 pivotal trial is now recruiting, supporting continued clinical momentum and reinforcing the therapy’s longer-duration efficacy profile.
One-year data showed sustained benefit for once-weekly canvuparatide as a potential parathyroid hormone (PTH) replacement therapy in chronic hypoparathyroidism. The Phase 3 pivotal trial is now recruiting, supporting continued clinical momentum and reinforcing the therapy’s longer-duration efficacy profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
